Report Overview

The US Chronic Pain Treatment market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of 6.8% during the forecast period

The chronic pain treatment industry is booming due to the increasing government support for chronic pain treatment, growing geriatric population, and rising prevalence of chronic health conditions. Among the most prevalent types of chronic pain are neck pain, lower back pain, facial pain, and migraine, due to which the demand for physiotherapy, medication, corrective surgery, psychological therapy, medical devices, therapeutic nerve blockers, and neuro ablation is quite high



Market Growth Drivers

The growth of the US pain treatment market is majorly due to the well-established business of painkiller medications as the first line of treatment. Post-surgical pain is one of the primary focuses of hospitals, where the cost of monitoring and the treatment of adverse effects create the major demand for pain treatment drugs. Extensive research and developments in genomics will also drive the market growth. The growing burden of the aging population is expected to drive the growth of the market, as the prevalence of chronic pain is relatively high among the geriatric population and is considered to be an independent risk factor for mortality. The increasing product launches are also expected to drive the market. For instance, in March 2020, Biotricity Inc. launched an innovative pain treatment product with CPM Centres for Pain Management, a subsidiary of NeuPath Health. Thus, given the aforementioned factors, the pain treatment market is expected to grow significantly during the forecast period